Alshammari Fahad, Alharbi Alwaleed, Alshammari Reem Ali
Clinical Pharmacy Department, King Fahad Medical City, Riyadh, Saudi Arabia.
Clinical Pharmacy Department, King Saud University, Riyadh, Saudi Arabia.
Am J Case Rep. 2025 May 15;26:e945772. doi: 10.12659/AJCR.945772.
BACKGROUND Acute pancreatitis (AP) occurs when pancreatic enzymes activate within the pancreas, causing damage. In the USA, 210 000 patients are hospitalized annually due to AP. Although statin-induced pancreatitis is rare and often misdiagnosed, it is crucial to investigate, as avoiding the causative medication can prevent attacks. There is conflicting evidence, and further research is needed to determine if statins increase the risk of AP. CASE REPORT In this report, we detail the case of a 48-year-old man with a history of dyslipidemia, for which he was prescribed atorvastatin 40 mg/day as a lipid-lowering agent. He developed acute pancreatitis after using atorvastatin. He initially presented to the emergency room with worsening epigastric pain. Elevated levels of lipase, amylase, and alanine aminotransferases in laboratory tests indicated acute pancreatitis. Given these findings, supportive care was promptly initiated, and atorvastatin, identified as the potential trigger, was discontinued. Notably, the patient had no history of alcohol or tobacco use, and extensive diagnostic efforts ruled out other common causes of acute pancreatitis. The absence of other risk factors reinforced the likelihood that atorvastatin was responsible for his condition, as noted in Table 2. This case underscores the importance of careful monitoring of symptoms and laboratory findings in patients treated with statin medications, particularly when prescribed for dyslipidemia. CONCLUSIONS Documenting such unusual cases could help highlight the potential risks of acute pancreatitis associated with statin use.
急性胰腺炎(AP)是胰腺内的胰酶激活并造成损伤时发生的疾病。在美国,每年有21万患者因AP住院。尽管他汀类药物引起的胰腺炎很罕见且常被误诊,但进行调查很关键,因为停用致病药物可预防发作。现有相互矛盾的证据,需要进一步研究以确定他汀类药物是否会增加AP风险。
在本报告中,我们详细介绍了一名48岁男性的病例,他有血脂异常病史,为此他被处方每日服用40毫克阿托伐他汀作为降脂药。他在使用阿托伐他汀后发生了急性胰腺炎。他最初因上腹部疼痛加重前往急诊室。实验室检查中脂肪酶、淀粉酶和丙氨酸转氨酶水平升高表明患有急性胰腺炎。鉴于这些发现,立即开始了支持性治疗,并停用了被确定为潜在诱因的阿托伐他汀。值得注意的是,该患者无酗酒或吸烟史,广泛的诊断排除了急性胰腺炎的其他常见病因。如表2所示,没有其他风险因素增加了阿托伐他汀导致其病情的可能性。该病例强调了在使用他汀类药物治疗的患者中,尤其是在因血脂异常而开此类药物时,仔细监测症状和实验室检查结果的重要性。
记录此类不寻常病例有助于凸显与使用他汀类药物相关的急性胰腺炎的潜在风险。